Ali Keshavarz, Pharm.D., Ph.D.
About Ali Keshavarz, Pharm.D., Ph.D.
Ali Keshavarz, Pharm.D., Ph.D., is a Research Scientist at the National Institutes of Health, specializing in innovative pharmaceutical manufacturing and dosage control using 3D printing technologies. He has a background in pharmacy and research, having previously worked at Texas Tech University Health Sciences Center and Tehran University of Medical Sciences.
Work at National Institutes of Health
Ali Keshavarz has been employed as a Research Scientist at the National Institutes of Health since 2020. In this role, he focuses on advancing pharmaceutical research and development. His work includes developing innovative approaches to oral pharmaceutical manufacturing and dosage control utilizing advanced 3D printing technologies. Keshavarz's research contributes to the field of drug delivery and formulation, aiming to improve therapeutic outcomes.
Education and Expertise
Ali Keshavarz earned his Doctor of Pharmacy (Pharm.D.) from Tehran University of Medical Sciences, completing his studies from 2005 to 2011. He later pursued a Doctor of Philosophy (Ph.D.) at Texas Tech University Health Sciences Center, where he studied from 2015 to 2020. His educational background equips him with a strong foundation in pharmaceutical sciences, pharmacokinetics, and drug development.
Background
Before joining the National Institutes of Health, Keshavarz worked at Texas Tech University Health Sciences Center as a Ph.D. Research Assistant from 2015 to 2020. He also served as a Teacher Assistant and Tutor during his time there. Prior to that, he completed his Pharm.D. at Tehran University of Medical Sciences from 2013 to 2015. His experiences span both educational and research environments, contributing to his expertise in pharmaceutical sciences.
Research Contributions
Keshavarz has made significant contributions to pharmaceutical research, including the development of a microfluidic platform and flow cytometry method for detecting circulating endothelial cells as a novel biomarker for early diagnosis of pulmonary arterial hypertension (PAH). He has also conducted a randomized clinical trial to monitor the effects of anti-PAH treatments using novel biomarkers. His research includes creating organ-on-chip models to simulate the microenvironment of cardiopulmonary diseases.
Publications and Projects
Ali Keshavarz has published five original research articles and one review article in high-impact journals, focusing on nanomedicine-based targeted drug delivery formulations. His research projects include nanoformulation targeted therapeutics for pulmonary diseases, emphasizing pharmacokinetics and pharmacodynamics modeling. He has participated in evaluating ANDA formulations for bioequivalence and stability studies, further showcasing his expertise in drug development.